The Emirates Drug Establishment and Insilico Medicine announced ISM0387, a cancer drug candidate discovered entirely using AI within the UAE.
Detail
- The compound ISM0387 targets aggressive brain tumors and was developed in under 12 months, a process that traditionally takes more than a decade.
- The Emirates Drug Establishment and Insilico Medicine announced ISM0387, a cancer drug candidate discovered entirely using AI within the UAE.
- The compound targets the PRMT5 enzyme in MTAP-deleted cancers, showing promise against aggressive brain tumors that are among the hardest to treat.
- Insilico’s Chemistry42 platform screened more than 90 molecules in six months, compressing a phase that traditionally takes more than four years.
- The announcement marks a major step for the UAE’s ambition to become a regional hub for AI-driven pharmaceutical research and advanced healthcare innovation.
- The key next stage will be preclinical testing, followed by clinical trials to determine whether the compound is safe and effective in humans.
What’s Next?
The achievement is promising, but the hard truth is that discovering a drug candidate is only the beginning. Proving safety, efficacy, and regulatory viability is the real test.
